In the present study, we investigated whether the anti-VEGFR-1 D16F7 mAb may hamper the ability of melanoma cells to adhere to the sVEGFR-1, invade the ECM and transmigrate through an endothelial cell monolayer in response to PlGF and whether these effects may translate in vivo into a reduced invasiveness and infiltrative potential of melanoma in the surrounding tissues. This evidence concerns the gene FLT1 and melanoma.